Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2018

View Archived Issues

Patient enrollment ongoing in phase I trial of the GBM vaccine candidate VBI-1901

Novartis patents novel HBsAg secretion inhibitors

Baxter buys two hemostasis products from Mallinckrodt

The Medicines Co. closes sale of infectious disease business unit to Melinta Therapeutics

TG Therapeutics obtains rights to Jiangsu Hengrui's BTK inhibitor program

Machine learning framework allows 99% accurate ligand binding predictions

Lenvima plus Keytruda obtains FDA breakthrough therapy designation in RCC

Axsome Therapeutics announces results of IDMC interim analysis of COAST-1 and CREATE-1 trials

Novel polycomb protein EED inhibitors identified at Novartis

Roche discovers novel cannabinoid CB2 receptor ligands

Incysus submits second IND application to FDA

AVID-200 shows promise for the treatment of myelodysplastic syndrome-related anemia

Nerviano Medical Sciences patents new HsPEK inhibitors

Global Blood Therapeutics' voxelotor given breakthrough therapy designation for sickle cell disease

Molecular Partners reports initial data from phase II study of MP-0250 in multiple myeloma

Adapsyn enters into research collaboration with Pfizer

GenSight cleared by MHRA to begin phase I/II study of GS-030 gene therapy for retinitis pigmentosa

Teijin returns somavaratan rights to Versartis

European Commission extends Orkambi marketing authorization to children aged 6-11 years

Akcea Therapeutics starts phase IIb study of AKCEA-APOCIII-LRx

Axovant corrects data from pilot phase II study of nelotanserin

Advanced Proteome Therapeutics and Heidelberg Pharma advance collaboration

JTZ-951, a HIF-PH inhibitor, shows positive results for treating renal anemia

Japanese submission seeks approval of blinatumomab for relapsed or refractory B-cell precursor ALL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...